Document is current
Any future updates will be listed below
-
Authors
Willemsen, Annelieke E. C. A. B. https://orcid.org/0000-0003-2433-1915
Krausz, Sarah
Ligtenberg, Marjolijn J. L.
Grünberg, Katrien
Groen, Harry J. M.
Voest, Emile E.
Cuppen, Edwin P. J. G.
van Laarhoven, Hanneke W. M.
van Herpen, Carla M. L.
-
Funding
Funding for this research was provided by:
Citrien Foundation
- License Information
-
More Information
Article History
Received: 21 January 2019
Revised: 3 May 2019
Accepted: 7 May 2019
First Online: 27 May 2019
Competing interest
: M.J.L.L: Consultant or advisory role: AstraZeneca, Bayer, Janssen Pharmaceuticals, Merck, Nimagen, Roche. Research funding: AstraZeneca, Bristol-Myers Squibb, Illumina. H.J.M.G: Consultant or advisory role: BMS, Merck, MSD, Pfizer, Novartis, and AstraZeneca. Research funding: Novartis, Roche, Pfizer, AstraZeneca, BMS, MSD, Merck, and Abbvie. E.E.V: is legally responsible for all contracts between pharma and the Netherlands Cancer Institute. H.W.M.v.L: Consultant or advisory role: BMS, Cerenis, Lilly, and Nordic Pharma; Research funding: Bayer, BMS, Celgene, Janssen, Lilly, Nordic Pharma, Philips, and Roche. C.M.L.v.H: Consultant or advisory role: BMS, Ipsen, Merck, MSD, Pfizer, and Sanofi; Research funding: AstraZeneca, MSD, Ipsen, Merck, and Philips.
: All respondents provided consent.
: This work was sponsored by Citrien foundation ().
: Not applicable.
: The data generated and analysed for the current investigation are not publicly available but are available at from the corresponding author on reasonable request.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
